CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 55 filers reported holding CABALETTA BIO INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,379,099 | +26.2% | 222,017 | +7.1% | 0.00% | – |
Q2 2023 | $2,677,031 | +60.0% | 207,361 | +2.5% | 0.00% | – |
Q1 2023 | $1,673,484 | -9.6% | 202,356 | +1.1% | 0.00% | – |
Q4 2022 | $1,851,435 | +1583.1% | 200,155 | +18.1% | 0.00% | – |
Q3 2022 | $110,000 | -14.7% | 169,420 | +39.0% | 0.00% | – |
Q2 2022 | $129,000 | -36.5% | 121,900 | +22.0% | 0.00% | – |
Q1 2022 | $203,000 | +6.3% | 99,897 | +97.5% | 0.00% | – |
Q4 2021 | $191,000 | -80.3% | 50,571 | -36.7% | 0.00% | – |
Q3 2021 | $972,000 | +3.4% | 79,918 | -26.8% | 0.00% | – |
Q2 2021 | $940,000 | +257.4% | 109,209 | +361.2% | 0.00% | – |
Q1 2021 | $263,000 | -38.1% | 23,678 | -30.5% | 0.00% | – |
Q4 2020 | $425,000 | -13.6% | 34,062 | -24.9% | 0.00% | – |
Q3 2020 | $492,000 | +19.4% | 45,344 | +22.6% | 0.00% | – |
Q2 2020 | $412,000 | +904.9% | 36,987 | +560.4% | 0.00% | – |
Q1 2020 | $41,000 | -71.5% | 5,601 | -45.8% | 0.00% | – |
Q4 2019 | $144,000 | – | 10,330 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |